News >

Perl Highlights Latest CAR T-Cell Therapy Advances

Caroline Seymour
Published: Monday, Mar 05, 2018

Alexander E Perl, MD

Alexander E Perl, MD
The addition of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia (ALL) has transformed the treatment paradigm, explains Alexander Perl, MD.

, Perl, an associate professor of medicine at the University of Pennsylvania, discussed the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.

OncLive: CAR T-cell therapy was recently named ASCO’s Cancer Advance of the Year. How has this treatment changed the paradigm for hematologic malignancies, such as ALL?

Perl: The CD19-directed therapies have really changed that process, whether it’s panitumumab (Vectibix)—which is an antibody that targets CD19 and directs T cells to it—or more recently, CAR T-cell therapies. Now, we are seeing both high rates of response and much more durable responses. In particular, with CAR T-cell therapy, not all of these patients need a subsequent transplant because patients who get durable responses and persistence of their CAR T cells can live without additional therapy in sustained remissions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication